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Breast cancer is the most common cause of cancer 
mortality in women worldwide and places an increasing 
burden on health services in both the developing and 
developed world.[1] Although mortality has decreased 
over the past two decades, incidence rates continue to 
increase, particularly in developing countries where the majority of cases 
are diagnosed at an advanced stage. Breast cancer survival rates also vary 
greatly between high- and low-income countries, with low survival rates 
explained mainly by late detection in resource-restricted countries. 
Breast cancer is a heterogeneous disease characterised by genetically 
distinct subtypes that differ in their response to treatment. [2] In 
approximately 20% of breast tumours, over-expression of the human 
epidermal growth factor receptor 2 (HER2) gene is associated with 
a poor prognosis and resistance to tamoxifen and methotrexate-
containing chemotherapy regimens, while targeted immunotherapy 
with Herceptin (trastuzumab) reduces the recurrence rate in these 
patients by about 50%. Patients with hormone-dependent breast 
cancer usually respond to a 5-year course of selective oestrogen 
receptor (ER) modulators, ovarian suppression or aromatase 
inhibitors. Chemotherapy is generally the only treatment option 
available for patients with the most aggressive subtype, known 
as basal-like or triple-negative breast cancer. The benefits of 
chemotherapy for triple-negative and HER2-positive tumours are 
well documented. Conversely, only a small minority of patients with 
ER-positive, progesterone receptor (PR) positive and HER2-negative 
tumours will benefit from chemotherapy, while all patients with such 
tumours offered chemotherapy are exposed to its side-effects.
Traditional guidelines for the use of adjuvant chemotherapy use 
tumour extent, lymphatic involvement and cellular morphology as 
a surrogate for tumour biology. Unfortunately, this correlates poorly 
and tends to overestimate the risk of systemic disease. Over the past 
20 years, extensive research has been performed into genetic profiling 
of breast tumours to more accurately identify poor prognostic tumour 
subtypes. Several tests have been developed commercially, of which 
MammaPrint and Oncotype Dx are available in South Africa (SA). 
MammaPrint uses a highly versatile microarray platform reflects the 
hallmarks of cancer-related biology for classification of early-stage breast 
cancer into low- or high-risk groups for chemotherapy selection. [3] It 
has been validated in at least 3 independent studies, with clinical utility 
confirmed by a recent prospective 5-year follow-up trial. [4] Further 
refinement of the test in 2010 enabled sub-classification of tumour 
tissue into luminal A, luminal B, HER2-positive and basal-like subtypes 
(BluePrint). This distinction cannot be achieved by standard pathology[5] 
and demonstrates the power of the microarray platform as a discovery 
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Background. Clinical and pathological parameters may overestimate the need for chemotherapy in patients with early-stage breast cancer. More 
accurate determination of the risk of distant recurrence is now possible with use of genetic tests, such as the 70-gene MammaPrint profile. 
Objectives. A health technology assessment performed by a medical insurer in 2009 introduced a set of test eligibility criteria – the 
MammaPrint Pre-screen Algorithm (MPA) – applied in this study to determine the clinical usefulness of a pathology-supported genetic 
testing strategy, aimed at the reduction of healthcare costs.
Methods. An implementation study was designed to take advantage of the fact that the 70-gene profile excludes analysis of hormone receptor and 
human epidermal growth factor receptor 2 (HER2) status, which form part of the MPA based partly on immunohistochemistry routinely performed 
in all breast cancer patients. The study population consisted of 104 South African women with early-stage breast carcinoma referred for MammaPrint. 
For the MammaPrint test, RNA was extracted from 60 fresh tumours (in 58 patients) and 46 formalin-fixed, paraffin-embedded (FFPE) tissue samples. 
Results. When applying the MPA for selection of patients eligible for MammaPrint testing, 95 of the 104 patients qualified. In this subgroup 
62% (59/95) were classified as low risk. Similar distribution patterns for risk classification were obtained for RNA extracted from fresh 
tumours v. FFPE tissue samples.
Conclusions. The 70-gene profile classifies approximately 40% of early-stage breast cancer patients as low-risk compared with 15% using 
conventional criteria. In comparison, more than 60% were shown to be low risk with use of the MPA validated in this study as an appropriate 
strategy to prevent chemotherapy overtreatment in patients with early-stage breast cancer. 
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tool for ongoing research, based on the ~25  000 genes in the human 
genome evaluated during development of the MammaPrint test. 
In a separate readout from the same microarray platform, 
quantitative gene expression levels of ER, PR and HER2 
(TargetPrint) are determined and provide additional confirmation 
of immunohistochemistry (IHC) and/or fluorescence in situ 
hybridisation (FISH) results at the RNA level. High concordance 
with IHC/FISH, demonstrated in the first 800 primary breast 
cancers of patients enrolled in the Microarray In Node-negative 
and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy 
(MINDACT) trial and in over 600 samples previously tested by 
Roepman et al.[6] for ER, PR and HER2 status, confirmed the 
robustness of the microarray platform. Multi-gene expression tests 
that are based on real-time polymerase chain reaction (RT-PCR) 
methodology, such as Oncotype Dx, have been criticised for lack 
of reproducibility in determination of HER2 overexpression, which 
forms an integral part of the recurrence score.[7,8] 
MammaPrint is the only test cleared by the US Food and Drug 
Administration (FDA), and this independent confirmation of 
analytical and clinical validation provides a high level of confidence in 
test performance. 
A critical step during the implementation phase of new technologies 
is to understand where any additional information provided by a 
genomic test could fit into the context of the current clinicopathological 
prognostication of early-stage breast carcinoma. Traditionally, tumours 
with ER and/or PR overexpression that are HER2-negative, have shown 
the lowest benefit to the addition of adjuvant chemotherapy. The 
addition of anthracycline chemotherapy to Herceptin is considered 
standard of care, and HER2-positive tumours were expected to benefit 
little by further genetic profiling. Due to the lack of alternative treatment 
options in ER-, PR- and HER2-negative tumours, chemotherapy 
remains the only adjuvant option, and the use of MammaPrint would 
not alter the treatment plan. Therefore, the ability to base clinical 
decision-making on microarray analysis after exclusion of triple-
negative and HER2-positive patients following standard IHC and FISH 
assessments, was an important consideration. 
The likelihood that it would be most cost-effective to use 
MammaPrint in such a clinical intermediate group (ER-positive 
and HER2-negative) in the resource-poor SA context, prompted 
a local medical insurer to subject the 70-gene MammaPrint test 
to a health technology assessment (HTA) in 2009. The results of 
the HTA indicated a break-even-point for cost-effectiveness of 
the test (at R22  000 per test) at approximately R88  000 for the 
cost of chemotherapy.[9] In this model, conventional criteria for 
chemotherapy treatment, namely the St Gallen Index and Adjuvant! 
Online, were replaced with a newly defined MammaPrint Pre-screen 
Algorithm (MPA), which is further evaluated in the present study. 
Methods
Study design
This study was designed to evaluate the appropriateness of a screening 
step for the selection of patients for MammaPrint, where the test 
would have the greatest impact to reduce chemotherapy, namely 
in hormone receptor-positive, HER2-negative early-stage breast 
cancer patients. The MPA took advantage of the fact that the 70-gene 
profile excludes assessment of ER, PR and HER2, already determined 
routinely in all breast cancer patients, using less expensive IHC and 
FISH tests. In a separate readout of the microarray platform, the ER, 
PR and HER2 status was assessed quantitatively as a confirmation of 
these IHC results, and to help resolve cases with equivocal results.
The study protocol was approved by the Ethics Research Committee 
of the University of Stellenbosch (ref. number N09/06/166). 
Study participants
The study population included 104 SA patients with early-stage 
breast cancer referred for the MammaPrint test from participating 
clinicians. Two of these patients presented with >1 tumour. An 
online questionnaire was used to document clinical characteristics. 
Additional information was obtained from patient records for 
comparative analysis. 
Laboratory analysis
Histopathological diagnosis, including nodal status and assessment 
of ER, PR and HER2 status, was performed using standard IHC 
techniques and established pathology protocols. FISH was used to 
determine HER2 status in all 2+ immunohistochemistry-equivocal 
cases and to confirm gene amplification in 3+ IHC-positive cases. 
In samples taken from the same tumour with differing results, 
performed at different laboratories, 1+ IHC-negative cases may also 
have been subjected to FISH. 
For the MammaPrint test, tumour samples were obtained from 
fresh surgical biopsies (n=60) or formalin-fixed, paraffin-embedded 
(FFPE) tissue (n=46). Samples were transported to Agendia in 
the Netherlands under an export permit obtained from the SA 
Department of Health. Microarray analysis was performed only on 
specimens with at least 30% tumour as evaluated by an experienced 
histopathologist, in accordance with FDA requirements. 
Defining the MammaPrint criteria
The international MammaPrint selection criteria, that allow inclusion 
of ER-negative and HER2-positive breast cancer, were modified for 
use in the HTA being evaluated in this study (Table 1).
Statistical analysis
A cross tabulation with the Chi-square test was performed to 
compare the distribution of MammaPrint low- v. high-risk profiles 
obtained between fresh tumour biopsies and FFPE tissue. A one-way 
analysis of variance (ANOVA) was conducted to test for a relationship 
between risk classification and age of breast cancer diagnosis at the 
time that the MammaPrint test was performed.
Results
Table 2 summarises the clinical characteristics of the study population 
– 104 female early-stage breast cancer patients. Of the 106 tumour 
specimens analysed with MammaPrint, 60% were classified as low risk 
and 40% as high risk for breast cancer recurrence. Similar distribution 
patterns for MammaPrint low- v. high-risk profiles were obtained, 
irrespective of whether fresh tumour biopsies or FFPE tissue was used. 
The mean histopathological tumour size was 14.6 mm.
No statistically significant relationship was found between risk 
classification and age of the patient at diagnosis (p=0.19), although 
younger patients tended to have a high-risk MammaPrint profile. 
The youngest patient (24 years old) had a high-risk tumour and the 
oldest (78 years old) had a low-risk gene profile. Two patients, both 
older than 55 years of age, had multicentric lobular carcinomas. One 
patient was identified as low risk for both tumours, while the second 
patient had both a high- and low-risk tumour according to the 
MammaPrint profile, and was documented as high risk in Table 1. 
The tumours of these 2 patients were not graded. IHC results for ER, 
PR and HER2 status are not shown in Table 1 as these assessments 
formed part of the selection criteria for MammaPrint using the MPA.
When applying the criteria for selection of SA patients eligible 
for MammaPrint testing (Table 1), 95/104 patients qualified. In this 
subgroup 59 (62%) were classified as low risk and 36 (38%) as high 
risk, based on the 70-gene profile. The remaining 9 patients were 
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referred for MammaPrint before implementation of the MPA in 
2009 or opted for gene profiling outside the approved algorithm for 
medical aid reimbursement, as they refused chemotherapy based on 
clinicopathological features alone.
Discussion
The MPA developed in SA to reduce healthcare costs was validated in 
this translational research study as an appropriate strategy for selection 
of chemotherapy in patients with early-stage breast cancer. The process 
used to introduce the 70-gene MammaPrint test into the SA healthcare 
system included modification of the test selection criteria for local use, 
based on: (i) clinical experience, and (ii) establishment of an online 
database tool to provide support for reimbursement by funders and to 
facilitate long-term health outcome studies. 
A total of 104 early-stage breast cancer patients were included 
in the present study. When we applied the MPA for determination 
of MammaPrint testing eligibility, 95 patients qualified for gene 
profiling. Using the MammaPrint test, 62% of patients in this clinical 
intermediate subgroup were re-classified as low-risk for recurrence. 
The HTA, using a model that replaced the conventional criteria for 
chemotherapy treatment (i.e. the St Gallen Index and Adjuvant! 
Online) with the MammaPrint risk profile, initially indicated a 
theoretical increase from 15% to >40% of patients who could be 
spared adjuvant chemotherapy. The fact that HER2-positive breast 
cancer accounts for approximately 20% of all breast cancers and that 
these cases, as well as ER-negative tumours on IHC, are excluded 
from genomic testing when applying the SA criteria, could explain the 
relatively high percentage of low-risk tumours in our study cohort. 
Early-stage breast cancer patients with low-risk tumours can 
indeed safely be spared chemotherapy, as demonstrated recently by 
Drukker et al.[4] in the first prospective 5-year follow-up study performed 
for gene-profiling of breast cancer. One subject in this SA cohort 
with bilateral, MammaPrint low-risk tumours has remained disease 
free since 2008, despite a family history of early-onset breast cancer. 
The patient tested negative for mutations in the BRCA1 and 2 genes 
analysed separately using DNA extracted from blood. She was included 
in our clinical outcome study performed in the first 50 SA breast cancer 
patients,[10] which showed that 2 high-risk tumours and none of the 
low-risk tumours have recurred. This finding supported the treatment 
changes reported in 46% of cases discordant with conventional criteria, 
leading to a reduction in chemotherapy recommendations.
The proportion of low-risk patients identified using the MPA (62%) 
is in accordance with the results of Hartmann et al.,[11] who reported 
38/60 (63%) female patients as low risk using similar eligibility criteria 
for the 70-gene MammaPrint test: pT1c-3, pN0-1a, grade 2/3, hormone 
receptor-positive, HER2-negative tumour. While previous studies 
suggested that the amount of prognostic information contained in 4 
standard IHC assays – ER, PR, HER2, and Ki-67 – is similar to that 
of the Oncotype DX recurrence score,[12] Hartmann et al.[11] confirmed 
that MammaPrint provides further risk stratification over and above 
that obtained by standard pathology tests. These findings supported 
the development of the MPA as a pre-screen prior to MammaPrint 
testing in the resource-poor SA context. In a direct comparison of 
the cost-effectiveness of the 2 different genomic profiling tests using a 
Markov model, Yang et al.[13] demonstrated MammaPrint to be the most 
cost-effective. Several studies demonstrated greater cost-effectiveness in 
patients with ER-positive tumours, which is in accordance with the HTA 
performed in the SA population, based partly on the exclusion of patients 
with ER-negative and HER2-positive tumours for MammaPrint testing. 
For breast cancer patients to benefit from new technologies, an 
increased focus on translational research is required to move basic 
Table 1. Modification of the international criteria for MammaPrint for reimbursement purposes in SA
International SA
Tumour size (cm) <5.0 ≤4
Lymph nodes, n ≤3 ≤3
Stage I - II I - II
Hormone receptor ER-positive/-negative ER-positive
PR-positive/-negative
HER2 Positive/negative Negative
Therapy Tamoxifen independent No neo-adjuvant therapy
SA = South Africa; ER = oestrogen receptor; PR = progesterone receptor; HER2 = human epidermal growth factor receptor 2.
Table 2. Clinical characteristics of tumours from female breast 








Total 104 62 (60) 42 (40)
Specimen
Fresh 58 33 (58) 25 (42)
FFPE 46 29 (63) 17 (37)
Age (years), mean 54 55 52
<36 4 1 3
36 - 45 16 9 7
46 - 55 40 24 16
>55 44 28 16
Pathology type
Ductal 85 51 34
Lobular 12 7 5
Mucinous 2 2 0
N/A 5 2 3
Pathology grade
1 36 24 12
2 36 21 15
3 9 3 6
N/A 23 14 9
FFPE = formalin-fixed, paraffin-embedded, N/A = not available.
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science into clinical and public medical practice.[14] The first step to 
incorporate gene expression profiling into clinical management of 
early-stage breast cancer patients in SA involved a feasibility study of 
the surgical procedure for specimen collection for the MammaPrint 
test.[15] The 70-gene MammaPrint test initially required a fresh 
tumour biopsy taken during surgery for microarray analysis, which 
was placed into a preservative solution and shipped to the reference 
laboratory at room temperature. Since the beginning of 2012, the 
option of using FFPE tumour tissue has also become available for 
the MammaPrint test. Initially, using a fresh biopsy to perform the 
test, a relatively high failure rate of 23% (18/78) was experienced, 
mainly due to the inability to meet the FDA requirement of at least 
30% tumour cell tissue. It also required the pre-operative planning 
for tissue collection and storage of the tissue in an appropriate 
medium until the final tumour histopathology became available. In 
comparison, all 46 specimens tested to date using FFPE have been 
successfully analysed using fixed tissue collected during surgery or 
core needle biopsies.
The use of FFPE, instead of fresh surgical biopsies, greatly 
enhanced the accessibility and convenience of the MammaPrint 
test in SA and elsewhere. Our finding of a similar distribution for 
MammaPrint low- v. high-risk profiles using fresh tumour biopsies 
or FFPE tissue confirmed the feasibility of RNA extraction from 
FFPE specimens for use in microarray analysis. Analytical validation 
using FFPE specimens was confirmed by excellent agreement with 
IHC/FISH results for the determination of HER2 status using 
microarray analysis and was found to be particularly useful to 
help resolve borderline cases (data not shown). Discrepancies may 
arise due to subjective interpretation of IHC and FISH results, 
arbitrary cut-off levels for positive results that may differ between 
the commercial kits, or due to a low percentage of invasive tumour 
in the tissue block when performing RT-PCR.[7,8] Our pathology-
supported genetic testing strategy enables the evaluation of a 
combination of tests most likely to overcome the limitations of a 
single test procedure.
For both specimen types, the low-risk MammaPrint profile was 
shown to be approximately 60%, which implies safe avoidance of 
chemotherapy in this subgroup.
The HTA-based recommendations for use of the MammaPrint 
70-gene profile in SA breast cancer patients initially included a 
requirement that the breast tumour should range between 1 and 
4 cm in diameter. Recently, this requirement was modified to include 
tumours <1 cm and core biopsies, due to the change of sampling 
from fresh biopsies to FFPE specimens for microarray analysis. 
The international criteria for MammaPrint include tumours up 
to 5 cm and are independent of ER/HER2 status and treatment 
regimes. Furthermore, stage I or II disease, with a maximum of 3 
nodes positive for disease, are eligible for MammaPrint referral. 
Although axillary lymph node status is an important prognostic 
factor, 25 - 30% of node-positive patients remain free of distant 
metastasis. Mook et al.[16] have demonstrated that the 70-gene 
signature can predict disease outcome in breast cancer patients with 
1 - 3 positive lymph nodes. The conclusion was that MammaPrint 
accurately identifies patients with an excellent disease outcome in 
node-positive breast cancer, who may be safely spared adjuvant 
chemotherapy. Some patients in our cohort refused chemotherapy, 
yet opted to have gene profiling done outside the approved protocol 
for medical aid reimbursement. These included patients with 4 nodes 
positive for disease, triple-negative or HER2-positive tumours. Those 
found to be low risk despite a clinical high-risk profile could be 
reassured that chemotherapy might be safely avoided, as supported 
by the findings of Glück et al.[5] The results of this retrospective 
analysis on prospectively collected tumour specimens accurately 
predicted response to chemotherapy and showed a 5-year survival 
benefit in luminal B, HER2-positive and basal-type tumours.[5] The 
identification of a biological HER2-negative subgroup despite IHC/
FISH positivity may potentially lead to an extension of the MPA and 
further saving of healthcare costs in SA.
Use of gene profiling raises the confidence levels of clinicians 
regarding their treatment decisions.[9] Traditionally, results generated 
in the laboratory rely on the clinician to make a diagnosis and 
provide the appropriate treatment. Evaluation of the MPA in routine 
clinical practice performed in this study led to the development 
and implementation of an integrative pathology-supported genetic 
testing service for MammaPrint, whereby gene profiling is combined 
with pathological measurements to identify subgroups of patients 
requiring different treatment strategies. An online database tool 
is used to provide support for reimbursement by funders and to 
facilitate long-term health outcome studies. This integrative software 
tool, freely available to clinicians, should be seen as a platform where 
biology and the clinical components of medical judgement converge 
to assist clinicians in planning treatment of their patients. 
The continuing rise in healthcare costs is unsustainable without 
changes in how cancer care is provided and reimbursed by funders. 
A process has therefore been initiated to develop a coverage policy 
for genomic tests by insurers in SA, based on the MammaPrint 
experience. Implementation of the MPA as a screening step for 
selection of patients for MammaPrint had a significant impact on 
reducing chemotherapy in early-stage breast cancer patients. The 
cost-saving implications of this approach support incorporation of 
the comprehensive microarray platform into treatment planning to 
(i) select chemotherapy in relevant early-stage breast cancer patients, 
(ii) confirm receptor status by providing quantitative gene expression 
assessment, as well as (iii) provide molecular subtyping of luminal A 
and B verifying receptor pathway activity.
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